Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Toripalimab · Surufatinib · Neoadjuvant Immunochemotherapy · Chemoradiotherapy · Esophageal Squamous Cell Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Sun yat-sen University Cancer Center, Guangzhou, Guangdong, China
Contact: Study coordinator (Bo Qiu) · qiubo@sysucc.org.cn · 02087343031

Study leads

Hui Liu
Principal Investigator
Sun yat-sen universtiy cancer center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

PDT For Induction Therapy For Head And Neck Cancer

Squamous Cell Carcinoma · Head and Neck Cancer Squamous Cell Carcinoma · Head and Neck Cancer

Abroad (travel likely)RecruitingPHASE2

Boston, United States · Boston, United States

Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer

Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Xi'an, China · Xi'an, China

Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma

Locally Advanced Hypopharyngeal Carcinoma

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

Toripalimab Combined With Definitive CCRT for LACC Patients

Cervical Cancer · Chemoradiotherapy · Immunotherapy

Abroad (travel likely)Recruiting

Shanghai, China